Imbalance of the Ras signaling pathway is a major hallmark of human cancer. In this context, activating point mutations of the K-ras oncogene are a common feature of many tumor types. The discovery of methylation-mediated silencing of the Ras-effector homologue RASSF1A has revealed another way by which this cellular pathway may be altered. Inactivation by hypermethylation of a RASSF1A homologue, NORE1A, has recently been observed in human cancers. If both K-ras and NORE1A act in the same pathway, simultaneous molecular lesions in the two genes in the same tumor should be a rare event.
Imbalance of the Ras signaling pathway is a major hallmark of human cancer. In this context, activating point mutations of the K-ras oncogene are a common feature of many tumor types. The discovery of methylation-mediated silencing of the Ras-effector homologue RASSF1A has revealed another way by which this cellular pathway may be altered. Inactivation by hypermethylation of a RASSF1A homologue, NORE1A, has recently been observed in human cancers. If both K-ras and NORE1A act in the same pathway, simultaneous molecular lesions in the two genes in the same tumor should be a rare event.
To test whether this inverse association exists, we have analysed the K-ras mutational status and NORE1A CpG island hypermethylation of 61 non-small-cell lung carcinomas and the methylation status of the two other Ras effectors, RASSF1A and HRASLS. No association was found between the methylation status of NORE1A, RASSF1A and HRASLS or the status of K-ras with respect to the latter two genes. However, our results demonstrate that the epigenetic alteration of NORE1A is confined to lung tumors with a wild-type K-ras: 88% (15 of 17) of the tumors with NORE1 hypermethylation did not harbor a K-ras mutation (P ¼ 0.008, Fisher's exact test). Thus, the mutual exclusivity of the epigenetic and genetic alterations in the two genes of the Ras pathway suggests that they play a critical and cooperative role in human tumorigenesis. Keywords: K-ras; methylation; NORE1A; lung cancer It is widely accepted that the probability of simultaneous hits in the same molecular pathway in a given tumor is very low. This is exemplified by three major cellular networks: APC/b-catenin, p53/MDM2 and Rb/ p16
INK4b
. Thus, mutations in the regulatory domain of b-catenin and APC gene were found to be mutually exclusive in CRC, consistent with their similar effects on b-catenin stability and Tcf activation (Sparks et al., 1998) . Furthermore, it has been postulated that, since p53 is directly targeted in approximately 50% of human malignancies (Hainaut et al., 1997) , other mechanisms are required to shut down the p53 pathway in tumors with wild-type p53. These molecular lesions include p53 degradation mediated by the viral protein E6, the action of the oncogene MDM2 on p53 transcriptional activity repression and the mediation of p53 degradation, and the inactivation of p14 ARF by promoter hypermethylation (Esteller et al., 2000; Esteller et al., 2001 ), a key regulator of MDM2 activity. Finally, simultaneous inactivation of Rb and the p16
INK4a locus, which negatively regulates the phosphorylation of Rb, is rarely found in any tumor type (Serrano, 1997) .
Another crucial pathway in cell transformation is Ras signaling. The Ras family of small GTPases includes three highly similar p21 proteins: H-ras, N-ras and Kras. Mutations in the K-ras oncogene, which render the protein resistant to inactivation by regulatory GAP proteins (Malumbres and Barbacid, 2003) , have frequently been found in many tumor types, including colorectal, pancreatic and lung tumors. The activated RAS excites the MAP kinase pathway by recruiting the cytosolic proteins RAF and one of its members, BRAF, is mutated in human neoplasia (Davies et al., 2002) . Interestingly, BRAF mutations occur most frequently in the context of wild-type K-ras (Rajagopalan et al., 2002; Soares et al., 2003) .
From the epigenetic standpoint, methylation-associated silencing of RASSF1A has been observed in human cancers (Dammann et al., 2000; Burbee et al., 2001; Dammann et al., 2003) . RASSF1A is a major transcript produced from the RASSF1 gene, a RASeffector homologue located at the minimal homozygous deletion region at 3p21.3 in lung and breast cancers (Dammann et al., 2000; Vos et al., 2000) . Transfection of RASSF1A in cancer cells results in the suppression of colony formation, anchorage-independent soft agar growth and nude mouse tumorigenicity (Dammann et al., 2000; Dreijerink et al., 2001) . Some studies examining the association between RASSF1A hypermethylation and K-ras mutations indicate that these events rarely occur in the same tumors (van Engeland et al., 2002; Dammann et al., 2003) , while others have revealed no such association (Kim et al., 2003; Ramirez et al., 2003) . In relation to BRAF mutations, RASSF1A methylation seems to occur only in BRAF-mutationnegative thyroid tumors (Xing et al., 2004) .
Of greatest interest is the recent discovery of a new RASSF1 homologue, NORE1 (Khokhlatchev et al., 2002; Ortiz-Vega et al., 2002; Tommasi et al., 2002) , which also undergoes methylation-mediated silencing in human tumors (Hesson et al., 2003; Morris et al., 2003) . The mouse (Vavvas et al., 1998) and human (Hesson et al., 2003) NORE1 genes, also known as RASSF5, possess the Ras-association domain that is common in many Ras effectors (Ponting and Benjamin, 1996) . Furthermore, it has been observed that NORE1 mediates Ras-dependent apoptosis and that its reintroduction in defective cell lines impairs growth in soft agar and suppresses colony formation (Vos et al., 2003; Aoyama et al., 2004) . In a similar manner to RASSF1, a particular transcript from NORE1 that arose from its own, separate CpG island, NORE1A, is inactivated by DNA methylation in cancer cell lines and primary tumors (Hesson et al., 2003) . In cancer cell lines, treatment with a demethylating agent restores NORE1A expression (Hesson et al., 2003) . To test whether the epigenetic loss of NORE1A is directly linked with the disturbance of the Ras pathway during cellular transformation, we have simultaneously analysed the NOR-E1A CpG island methylation and K-ras mutational status of a collection of non-small-cell lung adenocarcinomas.
We extracted DNA from 61 non-small-cell lung adenocarcinomas provided by the Tumour Bank Network of the Spanish National Cancer Centre (CNIO), Madrid, Spain. Cases were selected on the basis of the availability of frozen tissue and were uniformly reviewed and classified as adenocarcinomas. Representative sections from tissue used for DNA extraction were stained with H&E. Freshly frozen tissue from tumors was dissected at the microscopy by the pathologist to ensure that specimens contained at least 75% tumor cells. Approximately 10-20 mm sections were collected from tumor samples and placed in 1% sodium dodecyl sulfate/proteinase K (10 mg/ml) at 581C overnight. Digested tissue was then subjected to phenol-chloroform extraction and ethanol precipitation.
We screened these tumoral DNAs for KRAS mutations at codon 12 using a highly sensitive polymerase chain reaction (PCR)-RFLP assay (Schimanski et al., 1999) . Mutant bands in the agarose gel were excised, purified (UltraClean 15 Kit, MOBIO Laboratories, CA, USA) and automatically sequenced in an ABI PRISM 3700 DNA Analyzer. We found that K-ras was mutated in 37.7% (23 of 61) of lung adenocarcinomas. This frequency is similar to those reported by other groups in non-small-cell lung tumors (Minna et al., 2002) . A representative example of the mutational study is shown in Figure 1 .
We then analysed the CpG island methylation status of NORE1A by methylation-specific PCR (MSP), as described previously (Hesson et al., 2003) , which distinguishes unmethylated from methylated alleles in a given gene on the basis of sequence changes produced after bisulfite treatment of DNA. This treatment converts unmethylated, but not methylated, cytosines to uracil. The subsequent PCR employed primers designed for either methylated or unmethylated DNA (Herman et al., 1996) . Placental DNA treated in vitro with SssI methyltransferase was used as a positive control for all methylated genes. We found that NORE1A was hypermethylated in 27.8% (17 of 61) of lung adenocarcinomas. To confirm the NORE1A methylation status of these malignancies, five methylated and 10 unmethylated tumors according to MSP were also analysed by bisulfite genomic sequencing. In all cases, we obtained the same results by both methods. Furthermore, all the normal lung (n ¼ 4) and normal lymphocytes (n ¼ 4) analysed were found unmethylated at the NORE1A CpG island. Representative examples of the NORE1A methylation analysis are shown in Figure 1 and the primers used are described in Table 1 .
Although the presence of methylation at these CpG sites and NORE1A transcriptional silencing has been demonstrated previously (Hesson et al., 2003) , we double checked this observation in a set of lung cancer cell lines (n ¼ 5). Two cell lines were found hypermethylated at the NORE1A CpG island by MSP and bisulfite genomic sequencing and did not express the NORE1A transcript. Treatment of these cell lines with the demethylating agent 5-aza-2 0 -deoxycytidine restored gene expression. The three remaining cell lines were found unmethylated at NORE1A and expressed its transcript. Representative examples of the NORE1A methylation and expression analysis are shown in Figure 1 .
To complement the study and to examine the relation between other Ras effectors and K-ras and NORE1A, we also analysed the CpG island methylation status of RASSF1A in the same tumors, as described previously (Burbee et al., 2001) . Furthermore, we also studied the methylation status of another Ras modulator, HRASLS. The HRASLS gene undergoes methylationassociated silencing in gastric carcinoma (Kaneda et al., 2002) and suppresses the cell transformation induced by H-ras (Akiyama et al., 1999; Ito et al., 2001) . We observed hypermethylation of RASSF1A and HRASLS in 27.8% (17 of 61) and 31.1% (19 of 61) of lung adenocarcinomas, respectively. Interestingly, no relation between the CpG island methylation status of NOR-E1A, RASSF1A and HRASLS was observed. Representative examples of the RASSF1A and HRASLA methylation analysis are shown in Figure 2 . The distribution of the tumors according to the hypermethylation status of the three genes is shown in Figure 3 .
Finally and most important, we compared the data from the K-ras mutational analysis against the CpG island hypermethylation pattern of the Ras effectors NORE1A, RASSF1A and HRASLS (Table 2) . Although no relation was found between the methylation status of RASSF1A or HRASLS and the presence or absence of K-ras mutation, our data showed that NORE1A promoter hypermethylation was almost exclusively confined to those lung adenocarcinomas with a wild-type K-ras gene: 88% (15 of 17) of the tumors with methylation at the NORE1A CpG island NORE1A, K-ras and lung cancer M Irimia et al harbored no K-ras mutations (P ¼ 0.008, Fisher's exact test). These results are presented graphically in Figure 3 . Table 2 summarizes the numbers in each subgroup. Our discovery that NORE1A hypermethylation and K-ras mutations in non-small-cell lung carcinomas are mutually exclusive suggests that NORE1A may play an independent and leading role, at least in this tumor type. In fact, loss of heterozygosity at the NORE1A chromosomal locus 1q32 has been found in around 30% of primary lung tumors and cancer cell lines (Virmani et al., 1998; Sanchez-Cespedes et al., 2001) . Our manuscript and another report (Hesson et al., 2003) present preliminary data, suggesting that the epigenetic inactivation of NORE1A will prove to be a common feature of various types of malignancy, similar to the case of RASSF1A. It would be very interesting to establish whether there is an inverse relation between NORE1A methylation and K-ras mutation in these new types. Finally, as new genes with putative inhibition effects on the Ras signaling pathway are discovered and evidence emerges of their methylation-associated silencing in cancer cells, such as described in the cases of RASSF1A, NORE1A and HRASLS, the comparative study of methylation and mutation patterns of all the genes in the Ras pathway will become essential. For example, we have shown that HRASLS methylation is not associated with the K-ras mutation, but it may have an important effect on those tumor types with H-ras mutations, such as nonmelanoma skin cancer. Also, the other genes involved in the Ras network such as hDAB2IP, a member of the Ras GTPase-activating family, undergoes promoter hypermethylation in the NORE1A, K-ras and lung cancer M Irimia et al transformed cells (Chen et al., 2003) , but this is almost the limit of our knowledge concerning these genes. How do these aberrantly methylated Ras effectors behave in the context of a neoplasm with mutations in other, as yet unexplored Ras genes, such as N-ras in myelodysplastic syndrome? Such questions seem certain to be answered in the near future. Important issues will be addressed that will be crucial to our better understanding not only of tumor biology but also of the pharmacogenomic context within which the promising new anticancer drugs with Ras-inhibitory effects (Zhu et al., 2003) will act.
